Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines

Table 2 mRNA expression case-control analysis results for the NCI60 panel using mRNA expression data from BioGPS

Gene	Probes	p value	Gene	Probes	p value
LPHN2	206953_s_at	0.6612		205337_at	0.0062
ROBO1	213194_at	0.5188		205338_s_at	0.0098
DCT
	213543_at	0.0095		216512_s_at	0.0053
	214492_at	0.0026		216513_at	0.0049
SGCD
	210329_s_at	0.0031		214611_at	0.0077
	GRIK1
	210330_at	0.0053		207242_s_at	0.0243
	215702_s_at	0.0293		205712_at	0.7332
	215703_at	0.0095	PTPRD	213362_at	0.6878
CFTR
	217026_at	0.0117		214043_at	0.7795
	205043_at	0.0074	SNTG1	220405_at	0.0154

Protein-coding genes which did not have any available probes to measure their expression (BTBD12, ZNF607) were excluded from this analysis along with cell lines that did not have data available. A total of 20 probes were available to help analyze the expression pattern of the 8 genes listed above. As well, only 54 of the cell lines (from the 58 used in the GWAS) were used in this analysis as the remainder lacked gene expression data. Expression differences between sensitive and resistant cell lines were considered to be significant if p < 0.05 for the Mann-Whitney U-test.

ISSN: 1755-8794